XML 25 R14.htm IDEA: XBRL DOCUMENT
v3.21.2

Note 9 - Earnings Per Share | 3 Months Ended
--- | ---
Sep. 30, 2021
Notes to Financial Statements |
Earnings Per Share [Text Block] | Note 9. Earnings Per Share: The following table reflects the calculation of basic and diluted earnings per share (in thousands, except per share amounts):
|  | Quarter Ended September 30, |
|  | 2021 |  |  | 2020 |
Earnings per share – basic: |  |  |  |  |  |  |  |
Net earnings, including noncontrolling interest |  | $ | 68,981 |  |  | $ | 33,395 |
Less net earnings (loss) attributable to noncontrolling interest |  |  | (634 | ) |  |  | - |
Net earnings attributable to Bio-Techne |  | $ | 69,615 |  |  | $ | 33,395 |
Income allocated to participating securities |  |  | (36 | ) |  |  | (21) |
Income available to common shareholders |  | $ | 69,579 |  |  | $ | 33,374 |
Weighted-average shares outstanding - basic |  |  | 39,094 |  |  |  | 38,536 |
Earnings per share - basic |  | $ | 1.78 |  |  | $ | 0.87 |
Earnings per share – diluted: |  |  |  |  |  |  |  |
Net earnings, including noncontrolling interest |  | $ | 68,981 |  |  | $ | 33,395 |
Less net earnings (loss) attributable to noncontrolling interest |  |  | (634 | ) |  |  | - |
Net earnings attributable to Bio-Techne |  | $ | 69,615 |  |  | $ | 33,395 |
Income allocated to participating securities |  |  | (36 | ) |  |  | (21 | )
Income available to common shareholders |  | $ | 69,579 |  |  | $ | 33,374 |
Weighted average shares outstanding - basic |  |  | 39,094 |  |  |  | 38,536 |
Dilutive effect of stock options and restricted stock units |  |  | 2,064 |  |  |  | 1,489 |
Weighted average common shares outstanding - diluted |  |  | 41,158 |  |  |  | 40,025 |
Earnings per share - diluted |  | $ | 1.69 |  |  | $ | 0.83 |
The dilutive effect of stock options and restricted stock units in the above table excludes all options for which the aggregate exercise proceeds exceeded the average market price for the period. The number of potentially dilutive option shares excluded from the calculation was 0.4 million and 1.5 million for the quarter ended September 30, 2021 and 2020, respectively.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -URI http://asc.fasb.org/topic&trid=2144383 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration